Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | May 01, 2023 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000086115 | |
Entity Registrant Name | SAFEGUARD SCIENTIFICS INC | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q1 | |
Document Fiscal Year Focus | 2023 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 1-5620 | |
Entity Incorporation, State or Country Code | PA | |
Entity Tax Identification Number | 23-1609753 | |
Entity Address, Address Line One | 150 N. Radnor Chester Road | |
Entity Address, City or Town | Radnor | |
Entity Address, State or Province | PA | |
Entity Address, Postal Zip Code | 19087 | |
City Area Code | 610 | |
Local Phone Number | 293-0600 | |
Title of 12(b) Security | common stock, par value $0.10 | |
Trading Symbol | SFE | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Small Business | true | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 16,307,737 |
Consolidated Balance Sheets (Cu
Consolidated Balance Sheets (Current Period Unuaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Current Assets: | ||
Cash and cash equivalents | $ 11,008 | $ 13,331 |
Restricted cash | 25 | 25 |
Marketable securities | 7,760 | 5,956 |
Ownership interests | 0 | 860 |
Prepaid expenses and other current assets | 1,345 | 1,251 |
Total current assets | 20,138 | 21,423 |
Right-of-use asset, net | 1,215 | 1,290 |
Ownership interests and advances | 11,991 | 14,545 |
Other assets | 383 | 434 |
Total Assets | 33,727 | 37,692 |
Current Liabilities: | ||
Accounts payable | 71 | 16 |
Accrued compensation and benefits | 99 | 507 |
Accrued expenses and other current liabilities | 539 | 865 |
Lease liability - current | 443 | 429 |
Total current liabilities | 1,152 | 1,817 |
Lease liability - non-current | 1,133 | 1,249 |
Other long-term liabilities | 50 | 50 |
Total Liabilities | 2,335 | 3,116 |
Commitments and contingencies (Note 9) | ||
Equity: | ||
Preferred stock, $0.10 par value; 1,000 shares authorized | 0 | 0 |
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 shares issued and outstanding at March 31, 2023 and December 31, 2022 | 2,157 | 2,157 |
Additional paid-in capital | 803,021 | 804,752 |
Treasury stock, at cost; 5,310 and 5,478 shares at March 31, 2023 and December 31, 2022, respectively | (46,379) | (48,410) |
Accumulated deficit | (727,382) | (723,898) |
Accumulated other comprehensive loss | (25) | (25) |
Total Equity | 31,392 | 34,576 |
Total Liabilities and Equity | $ 33,727 | $ 37,692 |
Consolidated Balance Sheets (_2
Consolidated Balance Sheets (Current Period Unuaudited) (Parentheticals) - $ / shares shares in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Preferred stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Preferred stock, shares authorized (in shares) | 1,000 | 1,000 |
Common stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Common stock, shares authorized (in shares) | 83,333 | 83,333 |
Common stock, shares issued (in shares) | 21,573 | 21,573 |
Common stock, shares outstanding (in shares) | 21,573 | 21,573 |
Treasury stock, shares (in shares) | 5,310 | 5,478 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
General and administrative expense | $ 1,185 | $ 1,234 |
Operating loss | (1,185) | (1,234) |
Other income (loss), net | (9) | (1,997) |
Interest income | 274 | 101 |
Equity income (loss), net | (2,564) | (3,579) |
Net income (loss) before income taxes | (3,484) | (6,709) |
Income tax benefit (expense) | 0 | 0 |
Net income (loss) | $ (3,484) | $ (6,709) |
Net income (loss) per share: | ||
Basic (in dollars per share) | $ (0.22) | $ (0.40) |
Diluted (in dollars per share) | $ (0.22) | $ (0.40) |
Weighted average shares used in computing income (loss) per share: | ||
Basic (in shares) | 16,072 | 16,587 |
Diluted (in shares) | 16,072 | 16,587 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Cash Flows from Operating Activities: | ||
Net cash used in operating activities | $ (928) | $ (1,001) |
Cash Flows from Investing Activities: | ||
Proceeds from sales of ownership interests | 850 | 298 |
Advances and loans to ownership interests | (250) | (3,400) |
Purchases of marketable securities | (7,690) | 0 |
Proceeds from sales and maturities in marketable securities | 6,000 | 0 |
Net cash (used in) provided by investing activities | (1,090) | (3,102) |
Cash Flows from Financing Activities: | ||
Repurchases of Company common stock | (75) | (779) |
Tax withholdings related to equity-based awards | (230) | (450) |
Net cash used in financing activities | (305) | (1,229) |
Net change in cash, cash equivalents and restricted cash | (2,323) | (5,332) |
Cash, cash equivalents and restricted cash at beginning of period | 13,356 | 24,764 |
Cash, cash equivalents and restricted cash at end of period | $ 11,033 | $ 19,432 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Treasury Stock, Common [Member] | Total |
Balance at Dec. 31, 2021 | $ (709,635) | $ (25) | $ 2,157 | $ 806,638 | $ (48,569) | $ 50,566 |
Balance (in shares) at Dec. 31, 2021 | 21,573 | 5,068 | ||||
Net income (loss) | (6,709) | 0 | $ 0 | 0 | $ 0 | (6,709) |
Repurchases of common stock | 0 | 0 | $ 0 | 0 | $ (779) | (779) |
Repurchases of common stock (in shares) | 0 | 148 | ||||
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | (1,019) | $ 1,322 | 303 |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) | 0 | (122) | ||||
Stock-based compensation expense | 0 | 0 | $ 0 | 168 | $ 0 | 168 |
Balance at Mar. 31, 2022 | (716,344) | (25) | $ 2,157 | 805,787 | $ (48,026) | 43,549 |
Balance (in shares) at Mar. 31, 2022 | 21,573 | 5,094 | ||||
Balance at Dec. 31, 2021 | (709,635) | (25) | $ 2,157 | 806,638 | $ (48,569) | 50,566 |
Balance (in shares) at Dec. 31, 2021 | 21,573 | 5,068 | ||||
Balance at Dec. 31, 2022 | (723,898) | (25) | $ 2,157 | 804,752 | $ (48,410) | 34,576 |
Balance (in shares) at Dec. 31, 2022 | 21,573 | 5,478 | ||||
Net income (loss) | (3,484) | 0 | $ 0 | 0 | $ 0 | (3,484) |
Repurchases of common stock | 0 | 0 | $ 0 | 0 | $ (75) | (75) |
Repurchases of common stock (in shares) | 0 | 25 | ||||
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net | 0 | 0 | $ 0 | (1,899) | $ 2,106 | 207 |
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares) | 0 | (193) | ||||
Stock-based compensation expense | 0 | 0 | $ 0 | 168 | $ 0 | 168 |
Balance at Mar. 31, 2023 | $ (727,382) | $ (25) | $ 2,157 | $ 803,021 | $ (46,379) | $ 31,392 |
Balance (in shares) at Mar. 31, 2023 | 21,573 | 5,310 |
Note 1 - General
Note 1 - General | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. The accompanying unaudited interim Consolidated Financial Statements of Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) were prepared in accordance with accounting principles generally accepted in the United States of America and the interim financial statement rules and regulations of the SEC. In the opinion of management, these statements include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the Consolidated Financial Statements. The interim operating results are not 10 10 2022 10 Liquidity As of March 31, 2023 In January 2018, may The Company believes that its cash and cash equivalents at March 31, 2023 one Principles of Accounting for Ownership Interests in Companies The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not third one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not not The Company accounts for ownership interests that are not Comprehensive Income (loss) During the quarter ended March 31, 2023 2022, no Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not |
Note 2 - Ownership Interests an
Note 2 - Ownership Interests and Advances | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | 2. The following summarizes the carrying value of the Company’s ownership interests and advances. March 31, 2023 December 31, 2022 (Unaudited - In thousands) Equity Method: Companies $ 7,083 $ 8,749 Private equity funds 97 97 7,180 8,846 Other Method: Companies, fair value - 860 Companies, fair value measurement alternative 1,067 1,067 Private equity funds, fair value measurement alternative 250 250 1,317 2,177 Advances to companies 3,494 4,382 $ 11,991 $ 15,405 There were no three March 31, 2023 2022, As of March 31, 2023 8 March 31, 2023 Company Name Safeguard Primary Ownership as of March 31, 2023 Accounting Method Aktana, Inc. 13.6% Equity Clutch Holdings, Inc. 41.7% Equity InfoBionic, Inc. 25.2% Equity meQuilibrium 31.3% Equity Moxe Health Corporation 19.3% Equity Prognos Health Inc. 28.4% Equity Syapse, Inc. 11.0% Equity Trice Medical, Inc. 11.6% Equity Summarized Financial Information The following table summarizes the statement of operations data for the companies accounted for under the equity method for the three March 31, 2023 2022 one not Three Months Ended March 31, 2023 2022 (Unaudited - In thousands) Results of Operations: Revenue $ 33,393 $ 38,811 Gross profit $ 21,842 $ 24,920 Net loss $ (22,829 ) $ (30,862 ) |
Note 3 - Acquisitions of Owners
Note 3 - Acquisitions of Ownership Interests | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Equity Method and Other Investments Disclosure [Text Block] | 3. The following is a summary of additional deployments during the three March 31, 2023 The Company funded $0.3 million of convertible loans to Trice Medical. The Company had previously deployed an aggregate of $12.0 million. Trice Medical is focused on orthopedic diagnostics using fully integrated camera-enabled technologies to provide clinical solutions to physicians. |
Note 4 - Fair Value Measurement
Note 4 - Fair Value Measurements | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 4. The Company categorizes its financial instruments into a three 1 3 Cash, cash equivalents and restricted cash approximate fair value due to their short term nature. Marketable securities consist of U.S. Treasury Bills and are carried at amortized cost, which approximates fair value at March 31, 2023. not 2 3 March 31, 2023 December 31, 2022. Carrying Fair Value Measurement at March 31, 2023 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 11,008 $ 11,008 $ — $ — Restricted cash $ 25 $ 25 $ — $ — Marketable securities—held-to-maturity: U.S. Government securities $ 7,760 $ 7,760 $ — $ — Carrying Fair Value Measurement at December 31, 2022 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 13,331 $ 13,331 $ — $ — Restricted cash $ 25 $ 25 $ — $ — Marketable securities—held-to-maturity: U.S. Government securities $ 5,956 $ 5,956 $ — $ — Ownership interests $ 860 $ 860 $ — $ — |
Note 5 - Stock-based Compensati
Note 5 - Stock-based Compensation | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 5. Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: Three Months Ended March 31, 2023 2022 (Unaudited - In thousands) General and administrative expense $ 292 $ 314 $ 292 $ 314 Stock-based compensation consists of time based awards to employees, liability based awards to employees to be settled in stock, performance based awards to employees, other non-employee grants and liability based awards to Directors for quarterly and annual services. During the three March 31, 2023 2022 three March 31, 2023 |
Note 6 - Income Taxes
Note 6 - Income Taxes | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 6. The Company recorded no three March 31, 2023 2022 not three March 31, 2023 three March 31, 2023 no |
Note 7 - Net Income (Loss) Per
Note 7 - Net Income (Loss) Per Share | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 7. The calculations of net income (loss) per share were as follows: Three Months Ended March 31, 2023 2022 (Unaudited - In thousands, except per share data) Basic: Net income (loss) $ (3,484 ) $ (6,709 ) Weighted average common shares outstanding 16,072 16,587 Net income (loss) per share $ (0.22 ) $ (0.40 ) Diluted: Net income (loss) for dilutive share computation $ (3,484 ) $ (6,709 ) Number of shares used in basic per share computation 16,072 16,587 Unvested restricted stock and DSU's — — Employee stock options — — Weighted average common shares outstanding 16,072 16,587 Net income (loss) per dilutive share $ (0.22 ) $ (0.40 ) Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs). If an equity method company has dilutive stock options, unvested restricted stock, DSUs or warrants, diluted net income (loss) per share is computed by first Diluted income (loss) per share do not • At March 31, 2023 2022 • At March 31, 2023 2022 |
Note 8 - Segment Reporting
Note 8 - Segment Reporting | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 8. The Company operates as one As of March 31, 2023 December 31, 2022 |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 9. In March 2019, June 2019. April 2026, A summary of the Company's operating lease cash flows at March 31, 2023 Operating lease payments Expected sublease receipts (Unaudited - In thousands) 2023 (nine months ending December 31) $ 456 $ 420 2024 613 573 2025 619 590 2026 207 199 2027 — — 2028 — — Thereafter — — Total future minimum lease payments 1,895 $ 1,782 Less imputed interest (319 ) Total operating lease liabilities $ 1,576 The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not no one The Company has provided a guarantee, which is fully funded by escrowed funds held by a third March 31, 2023 one In 2018, February 2019 June 2020, January 2018. June 2020 first may first second 60 zero March 31, 2022 2023. not three March 31, 2022 2023 March 31, 2023 The Company has agreements with certain remaining employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under employment and severance agreements for remaining employees was approximately $1.0 million at March 31, 2023 In June 2011, March 2012, July 2015 one 2014 one |
Note 10 - Equity
Note 10 - Equity | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | 10. In July 2015, not 2022 three March 31, 2023 In March 2022, May 2021 10b5 1 10b 18 1934, 2022 January 2022 |
Note 11 - Subsequent Event
Note 11 - Subsequent Event | 3 Months Ended |
Mar. 31, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 11. During April 2023, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Accounting Policies [Abstract] | |
Liquidity, Policy [Policy Text Block] | Liquidity As of March 31, 2023 In January 2018, may The Company believes that its cash and cash equivalents at March 31, 2023 one |
Investment, Policy [Policy Text Block] | Principles of Accounting for Ownership Interests in Companies The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not third one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not not The Company accounts for ownership interests that are not |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Income (loss) During the quarter ended March 31, 2023 2022, no |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not |
Note 2 - Ownership Interests _2
Note 2 - Ownership Interests and Advances (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block] | March 31, 2023 December 31, 2022 (Unaudited - In thousands) Equity Method: Companies $ 7,083 $ 8,749 Private equity funds 97 97 7,180 8,846 Other Method: Companies, fair value - 860 Companies, fair value measurement alternative 1,067 1,067 Private equity funds, fair value measurement alternative 250 250 1,317 2,177 Advances to companies 3,494 4,382 $ 11,991 $ 15,405 |
Schedule of Other Ownership Interests [Table Text Block] | Company Name Safeguard Primary Ownership as of March 31, 2023 Accounting Method Aktana, Inc. 13.6% Equity Clutch Holdings, Inc. 41.7% Equity InfoBionic, Inc. 25.2% Equity meQuilibrium 31.3% Equity Moxe Health Corporation 19.3% Equity Prognos Health Inc. 28.4% Equity Syapse, Inc. 11.0% Equity Trice Medical, Inc. 11.6% Equity |
Equity Method Investments [Table Text Block] | Three Months Ended March 31, 2023 2022 (Unaudited - In thousands) Results of Operations: Revenue $ 33,393 $ 38,811 Gross profit $ 21,842 $ 24,920 Net loss $ (22,829 ) $ (30,862 ) |
Note 4 - Fair Value Measureme_2
Note 4 - Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Carrying Fair Value Measurement at March 31, 2023 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 11,008 $ 11,008 $ — $ — Restricted cash $ 25 $ 25 $ — $ — Marketable securities—held-to-maturity: U.S. Government securities $ 7,760 $ 7,760 $ — $ — Carrying Fair Value Measurement at December 31, 2022 Value Level 1 Level 2 Level 3 (Unaudited - In thousands) Cash and cash equivalents $ 13,331 $ 13,331 $ — $ — Restricted cash $ 25 $ 25 $ — $ — Marketable securities—held-to-maturity: U.S. Government securities $ 5,956 $ 5,956 $ — $ — Ownership interests $ 860 $ 860 $ — $ — |
Note 5 - Stock-based Compensa_2
Note 5 - Stock-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Share-Based Payment Arrangement, Activity [Table Text Block] | Three Months Ended March 31, 2023 2022 (Unaudited - In thousands) General and administrative expense $ 292 $ 314 $ 292 $ 314 |
Note 7 - Net Income (Loss) Pe_2
Note 7 - Net Income (Loss) Per Share (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended March 31, 2023 2022 (Unaudited - In thousands, except per share data) Basic: Net income (loss) $ (3,484 ) $ (6,709 ) Weighted average common shares outstanding 16,072 16,587 Net income (loss) per share $ (0.22 ) $ (0.40 ) Diluted: Net income (loss) for dilutive share computation $ (3,484 ) $ (6,709 ) Number of shares used in basic per share computation 16,072 16,587 Unvested restricted stock and DSU's — — Employee stock options — — Weighted average common shares outstanding 16,072 16,587 Net income (loss) per dilutive share $ (0.22 ) $ (0.40 ) |
Note 9 - Commitments and Cont_2
Note 9 - Commitments and Contingencies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Notes Tables | |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | Operating lease payments Expected sublease receipts (Unaudited - In thousands) 2023 (nine months ending December 31) $ 456 $ 420 2024 613 573 2025 619 590 2026 207 199 2027 — — 2028 — — Thereafter — — Total future minimum lease payments 1,895 $ 1,782 Less imputed interest (319 ) Total operating lease liabilities $ 1,576 |
Note 1 - General (Details Textu
Note 1 - General (Details Textual) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Cash and Cash Equivalents, at Carrying Value | $ 11,008 | $ 13,331 |
Marketable Securities | $ 7,800 |
Note 2 - Ownership Interests _3
Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Equity Method Companies | $ 7,180 | $ 8,846 |
Ownership interests | 0 | 860 |
Other Method, fair value measurement alternative | 1,317 | 2,177 |
Advances to companies | 3,494 | 4,382 |
Investments and Advances to Affiliates, Current and Noncurrent | 11,991 | 15,405 |
Partnership Interest [Member] | ||
Equity Method Companies | 7,083 | 8,749 |
Ownership interests | 0 | 860 |
Other Method, fair value measurement alternative | 1,067 | 1,067 |
Private Equity Funds [Member] | ||
Equity Method Companies | 97 | 97 |
Other Method, fair value measurement alternative | $ 250 | $ 250 |
Note 2 - Ownership Interests _4
Note 2 - Ownership Interests and Advances - Schedule of Ownership Interests (Details) | Mar. 31, 2023 |
Aktana, Inc. [Member] | |
Ownership Interest | 13.60% |
Clutch Holdings [Member] | |
Ownership Interest | 41.70% |
InfoBionic, Inc. [Member] | |
Ownership Interest | 25.20% |
meQuilibrium [Member] | |
Ownership Interest | 31.30% |
Moxe Health Corporation [Member] | |
Ownership Interest | 19.30% |
Prognos Health, Inc. [Member] | |
Ownership Interest | 28.40% |
Syapse, Inc. [Member] | |
Ownership Interest | 11% |
Trice Medical, Inc. [Member] | |
Ownership Interest | 11.60% |
Note 2 - Ownership Interests _5
Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenue | $ 33,393 | $ 38,811 |
Gross profit | 21,842 | 24,920 |
Net loss | $ (22,829) | $ (30,862) |
Note 3 - Acquisitions of Owne_2
Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Dec. 31, 2022 | |
Equity Method Investments | $ 7,180 | $ 8,846 |
Trice Medical, Inc. [Member] | ||
Convertible Bridge Loan | 300 | |
Equity Method Investments | $ 12,000 |
Note 4 - Fair Value Measureme_3
Note 4 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured On Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
Reported Value Measurement [Member] | ||
Cash and cash equivalents | $ 11,008 | $ 13,331 |
Restricted cash | 25 | 25 |
U.S. Government securities | 5,956 | |
Ownership interests | 860 | |
Reported Value Measurement [Member] | US Treasury Securities [Member] | ||
U.S. Government securities | 7,760 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Cash and cash equivalents | 11,008 | 13,331 |
Restricted cash | 25 | 25 |
U.S. Government securities | 5,956 | |
Ownership interests | 860 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member] | ||
U.S. Government securities | 7,760 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Restricted cash | 0 | 0 |
U.S. Government securities | 0 | |
Ownership interests | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member] | ||
U.S. Government securities | 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Cash and cash equivalents | 0 | 0 |
Restricted cash | 0 | 0 |
U.S. Government securities | 0 | |
Ownership interests | $ 0 | |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member] | ||
U.S. Government securities | $ 0 |
Note 5 - Stock-based Compensa_3
Note 5 - Stock-based Compensation (Details Textual) - Share-Based Payment Arrangement, Nonemployee [Member] - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) | 240 | |
Restricted Stock [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares) | 28 | 10 |
Note 5 - Stock-based Compensa_4
Note 5 - Stock-based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
General and administrative expense | $ 292 | $ 314 |
General and Administrative Expense [Member] | ||
General and administrative expense | $ 292 | $ 314 |
Note 7 - Net Income (Loss) Pe_3
Note 7 - Net Income (Loss) Per Share (Details Textual) - $ / shares | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Share-Based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 8,000 | 21,000 |
Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share) | $ 10.37 | $ 10.37 |
Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | ||
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share) | $ 17.11 | |
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 0.3 | 200,000 |
Note 7 - Net Income (Loss) Pe_4
Note 7 - Net Income (Loss) Per Share - Calculations of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Basic: | ||
Net income (loss) | $ (3,484) | $ (6,709) |
Basic (in shares) | 16,072 | 16,587 |
Basic (in dollars per share) | $ (0.22) | $ (0.40) |
Diluted: | ||
Net income (loss) | $ (3,484) | $ (6,709) |
Basic (in shares) | 16,072 | 16,587 |
Unvested restricted stock and DSU's (in shares) | 0 | 0 |
Employee stock options (in shares) | 0 | 0 |
Diluted (in shares) | 16,072 | 16,587 |
Diluted (in dollars per share) | $ (0.22) | $ (0.40) |
Note 8 - Segment Reporting (Det
Note 8 - Segment Reporting (Details Textual) | 3 Months Ended |
Mar. 31, 2023 | |
Number of Operating Segments | 1 |
Note 9 - Commitments and Cont_3
Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
Long-term Incentive Plan, Payments | $ 0 | |||
Deferred Compensation Liability, Current and Noncurrent, Total | $ 0 | |||
Employee and Severance Agreement, Maximum Aggregate Exposure | $ 1,000 | |||
Employee and Severance Agreement, Maximum Aggregate Exposure, Shares (in shares) | 218,750 | |||
Amended and Restated Safeguard Scientifics Transaction Bonus Plan [Member] | ||||
Compensation, Cash Award | $ 0 | |||
Minimum [Member] | ||||
Long-term Incentive Plan, Bonus Pool Percent | 1% | |||
Maximum [Member] | ||||
Long-term Incentive Plan, Bonus Pool Percent | 1.30% | |||
Private Equity Funds [Member] | ||||
Guarantor Obligations, Current Carrying Value | $ 3,800 |
Note 9 - Commitments and Cont_4
Note 9 - Commitments and Contingencies - Operating Lease Cash Flow (Details) $ in Thousands | Mar. 31, 2023 USD ($) |
2023 (nine months ending December 31) | $ 456 |
2023 (nine months ending December 31) | 420 |
2024, Operating lease payments | 613 |
2024, Expected sublease receipts | 573 |
2025, Operating lease payments | 619 |
2025, Expected sublease receipts | 590 |
2026, Operating lease payments | 207 |
2026, Expected sublease receipts | 199 |
2027, Operating lease payments | 0 |
2027, Expected sublease receipts | 0 |
2028, Operating lease payments | 0 |
2028, Expected sublease receipts | 0 |
Thereafter, Operating lease payments | 0 |
Thereafter, Expected sublease receipt | 0 |
Total future minimum lease payments, Operating lease payments | 1,895 |
Total future minimum lease payments, Expected sublease receipt | 1,782 |
Less imputed interest, Operating lease payments | (319) |
Total operating lease liabilities, Operating lease payments | $ 1,576 |
Note 10 - Equity (Details Textu
Note 10 - Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||
Jan. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | Mar. 31, 2022 | Jul. 31, 2015 | |
Share Repurchase Program Authorized in July 2015 [Member] | |||||
Stock Repurchase Program, Authorized Amount | $ 25 | ||||
Treasury Stock, Shares, Acquired (in shares) | 0 | 0 | |||
Share Repurchase Program Authorized in March 2022 [Member] | |||||
Stock Repurchase Program, Authorized Amount | $ 3 | ||||
Treasury Stock, Shares, Acquired (in shares) | 25,096 | ||||
Treasury Stock Acquired, Average Cost Per Share (in dollars per share) | $ 4.09 |
Note 11 - Subsequent Event (Det
Note 11 - Subsequent Event (Details Textual) - USD ($) $ in Thousands | 1 Months Ended | ||
Apr. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 | |
Equity Method Investments | $ 7,180 | $ 8,846 | |
Prognos Health, Inc. [Member] | Subsequent Event [Member] | |||
Payments to Acquire Equity Method Investments | $ 3,000 | ||
Equity Method Investments | $ 14,600 |